MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 126012 | Name: Depreotide trifluoroacetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Depreotide is an ingredient in the diagnostic aid (radioactive imaging agent). echnetium Tc 99m labeled depreotide is a scintigraphic imaging agent that identifies somatostatin receptor-bearing pulmonary masses in patients presenting with pulmonary lesions on computed tomography and/or chest x-ray who have known malignancy or who are highly suspect for malignancy.

Chemical Structure

Depreotide trifluoroacetate
Depreotide trifluoroacetate
CAS#951756-09-5 (trifluoroacetate)

Theoretical Analysis

MedKoo Cat#: 126012

Name: Depreotide trifluoroacetate

CAS#: 951756-09-5 (trifluoroacetate)

Chemical Formula: C67H97F3N16O14S2

Exact Mass: 1470.6764

Molecular Weight: 1471.73

Elemental Analysis: C, 54.68; H, 6.64; F, 3.87; N, 15.23; O, 15.22; S, 4.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
951756-09-5 (trifluoroacetate) 161982-62-3 (free base)
Synonym
Depreotide trifluoroacetate; NeoSpect; Depreotide; P829; P-829; P 829
IUPAC/Chemical Name
(S)-2-((S)-3-(2-((2-((2S,5S,8S,11R,14S,17S)-11-((1H-indol-3-yl)methyl)-14-(4-aminobutyl)-5-benzyl-8-(4-hydroxybenzyl)-17-isopropyl-4-methyl-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexaazacyclooctadecan-2-yl)ethyl)thio)acetamido)-2-aminopropanamido)-6-amino-N-((R)-1-(((S)-1,6-diamino-1-oxohexan-2-yl)amino)-3-mercapto-1-oxopropan-2-yl)hexanamide 2,2,2-trifluoroacetate
InChi Key
ULBLQSNGKAZIES-KTABZWLNSA-N
InChi Code
InChI=1S/C65H96N16O12S2.C2HF3O2/c1-38(2)55-64(92)76-49(26-30-95-37-54(83)72-35-44(69)57(85)74-47(20-10-13-28-67)58(86)79-52(36-94)62(90)73-46(56(70)84)19-9-12-27-66)65(93)81(3)53(32-39-15-5-4-6-16-39)63(91)78-50(31-40-22-24-42(82)25-23-40)60(88)77-51(33-41-34-71-45-18-8-7-17-43(41)45)61(89)75-48(59(87)80-55)21-11-14-29-68;3-2(4,5)1(6)7/h4-8,15-18,22-25,34,38,44,46-53,55,71,82,94H,9-14,19-21,26-33,35-37,66-69H2,1-3H3,(H2,70,84)(H,72,83)(H,73,90)(H,74,85)(H,75,89)(H,76,92)(H,77,88)(H,78,91)(H,79,86)(H,80,87);(H,6,7)/t44-,46-,47-,48-,49-,50-,51+,52-,53-,55-;/m0./s1
SMILES Code
OC(C(F)(F)F)=O.CC([C@@H]1NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](N(C([C@@H](NC1=O)CCSCC(NC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCN)=O)CS)=O)CCCCN)=O)N)=O)=O)C)CC2=CC=CC=C2)=O)CC3=CC=C(C=C3)O)=O)CC4=CNC5=C4C=CC=C5)=O)CCCCN)=O)C
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,471.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Papathanasiou ND, Rondogianni PE, Pianou NK, Karampina PA, Vlontzou EA, Datseris IE. 99mTc-depreotide in the evaluation of bone infection and inflammation. Nucl Med Commun. 2008 Mar;29(3):239-46. doi: 10.1097/MNM.0b013e3282f20e30. PMID: 18349794. 2: Mena E, Camacho V, Estorch M, Fuertes J, Flotats A, Carrió I. 99mTc- depreotide scintigraphy of bone lesions in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1399-404. doi: 10.1007/s00259-004-1594-x. Epub 2004 Jun 19. PMID: 15221296. 3: Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I. 99mTc- depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine- negative thyroid cancer. J Clin Endocrinol Metab. 2006 Oct;91(10):3997-4000. doi: 10.1210/jc.2006-0825. Epub 2006 Aug 8. PMID: 16895961. 4: Yu F, Lv M, Cai H, Li D, Yuan X, Lv Z. Therapeutic effect of 188Re- MAG3-depreotide on non-small cell lung cancer in vivo and in vitro. Int J Clin Exp Pathol. 2013;6(3):421-30. Epub 2013 Feb 15. PMID: 23411669; PMCID: PMC3563183. 5: Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med. 2002 Apr;32(2):92-6. doi: 10.1053/snuc.2002.31564. PMID: 11965604. 6: Apostolopoulos DJ, Papandrianos NI, Symeonidis A, Spyridonidis T, Alexiou S, Zampakis P, Savvopoulos C, Vassilakos PJ, Matsouka P. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. Ann Nucl Med. 2010 Nov;24(9):639-47. doi: 10.1007/s12149-010-0405-7. Epub 2010 Aug 27. PMID: 20799079. 7: Van Den Bossche B, D'haeninck E, De Winter F, Van Belle S, Dierckx RA, Van De Wiele C. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer. Nucl Med Commun. 2004 Aug;25(8):787-92. doi: 10.1097/01.mnm.0000134934.87929.84. PMID: 15266172. 8: Xia W, Zhang X, Yu F, Wang P, Cai H, Hou R, Wang G, Yuan X, LV Z. Experimental study of 99mTc-depreotide preparation and its affinity with A549 cell. Front Biosci (Landmark Ed). 2011 Jun 1;16:2527-39. doi: 10.2741/3870. PMID: 21622193. 9: Harders SW, Madsen HH, Hjorthaug K, Rehling M, Rasmussen TR, Pedersen U, Pilegaard HK, Meldgaard P, Baandrup UT, Rasmussen F. Limited value of ⁹⁹mTc depreotide single photon emission CT compared with CT for the evaluation of pulmonary lesions. Br J Radiol. 2012 Jul;85(1015):e307-13. doi: 10.1259/bjr/10438644. PMID: 22745210; PMCID: PMC3474046. 10: Axelsson R, Herlin G, Bååth M, Aspelin P, Kölbeck KG. Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer. Acta Radiol. 2008 Apr;49(3):295-302. doi: 10.1080/02841850701793777. PMID: 18365818.